Patient Power
Research and clinical trials help lead to new treatments, especially targeted therapies. Now, patients with KRAS-mutated non-small cell lung cancer (NSCLC) have more options for treatment. Tarik Hadid, M.D., MPH, MS, FACP, medical oncologist and member of the Phase I Clinical Trials and Thoracic Oncology Multidisciplinary Teams at Karmanos, explained how KRAS inhibitors work for NSCLC patients who have the KRAS mutation.
Read the article here.